Photo by schluditsch from unsplash
DRESS: drug reaction with eosinophilia and systemic symptoms INTRODUCTION Brentuximab vedotin is a monoclonal antibody targeting CD30 cells, first approved by the Food and Drug Administration for the treatment of… Click to show full abstract
DRESS: drug reaction with eosinophilia and systemic symptoms INTRODUCTION Brentuximab vedotin is a monoclonal antibody targeting CD30 cells, first approved by the Food and Drug Administration for the treatment of CD30 cutaneous T-cell lymphoma in 2017. Although a nonspecific maculopapular rash was noted in 11% of patients treated with brentuximab vedotin during clinical trials, drug reaction with eosinophilia and systemic symptoms (DRESS) has not been previously described, to our knowledge. We report 2 cases of patients with CD30 cutaneous T-cell lymphoma who developed DRESS after initiation of brentuximab vedotin.
Journal Title: JAAD Case Reports
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!